Pre-implantation genetic testing (PGT) for monogenic or single-gene defects (PGT-M) and chromosomal structural rearrangements (PGT-SR), previously available under a pilot programme, are now classified as mainstream, regulated clinical services with effect from May 1.
PGT-M and PGT-SR, previously known as pre-implantation genetic diagnosis, have been available in Singapore since 2005 under a pilot programme.
No change has been made to the eligibility criteria for patients to receive these treatments. MOH said these services should be carried out only for couples at risk of passing on serious genetic disorders such as harlequin ichthyosis, beta thalassemia and Huntington’s disease.
“Based on findings from the pilot programme, PGT-M and PGT-SR were found to be safe and able to reduce the likelihood of live-born offspring being affected by these serious inheritable diseases.
The ministry said it had received nine applications from hospitals and clinical laboratories to offer PGT services as at May 1.
SOURCES- Strait Times
Written by Brian Wang, NExtbigfuture.com
Brian Wang is a Futurist Thought Leader and a popular Science blogger with 1 million readers per month. His blog Nextbigfuture.com is ranked #1 Science News Blog. It covers many disruptive technology and trends including Space, Robotics, Artificial Intelligence, Medicine, Anti-aging Biotechnology, and Nanotechnology.
Known for identifying cutting edge technologies, he is currently a Co-Founder of a startup and fundraiser for high potential early-stage companies. He is the Head of Research for Allocations for deep technology investments and an Angel Investor at Space Angels.
A frequent speaker at corporations, he has been a TEDx speaker, a Singularity University speaker and guest at numerous interviews for radio and podcasts. He is open to public speaking and advising engagements.